市场调查报告书
商品编码
1447739
软组织修復市场评估:按产品、应用、最终用户和地区划分的机会和预测(2017-2031)Soft Tissue Repair Market Assessment, By Product, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
全球软组织修復市场规模预计将从2023年的145.1亿美元成长到2031年的206.1亿美元,2024-2031年预测期间复合年增长率为4.48%,预计规模还将持续扩大。
支持该市场成长的主要因素包括增加资金支持与软组织修復相关的研究活动、老年人口的增加、运动相关损伤发生率的增加以及新产品的推出。
人口老化越来越容易患各种疾病,这增加了对软组织修復解决方案的需求。 随着年龄的增长,骨密度下降,使我们更容易骨折,并增加对骨科修復解决方案的需求。 此外,运动相关损伤数量的增加也增加了对不同类型软组织修復解决方案的需求,支持了市场的成长。 为了满足对软组织修復技术和产品不断增长的需求,一些主要进入者和新创公司正在进行大量投资以推出新颖的产品和技术。
研发活动的重要性日益增加支持市场成长
过去几年,各主要进入者和新创公司加大了研发活动的投资,以加速技术先进的软组织修復产品的开发。 Regenosca 是一家总部位于瑞士的新创公司,正在开发非侵入性植入物来取代患者的组织移植。 该公司开发的解决方案针对需要自体移植软组织修復手术的患者。 在 TissueSpan 植入物的帮助下,患者可以避免二次手术,减少併发症的风险、手术时间和疼痛。 该新创公司管道中的下一个产品是用于食道重建的植入物,取代患者目前使用的肠道组织和胃。
运动相关伤害的增加和人口老化将推动市场需求
人口老化的加剧和运动相关伤害数量的增加是支持软组织修復市场成长的主要因素。 运动伤害通常是由于直接撞击或过度使用特定身体部位而发生的。 当身体的一部分承受的力量超过其结构所能承受的力量时,也会发生这种情况。 据约翰霍普金斯大学医学中心称,大约有 3000 万青少年和儿童参加某种类型的有组织的运动,每年发生超过 350 万起伤害事件。
此外,在高龄化社会中,由于代谢功能障碍和生理变化,软组织更容易受到各种类型的伤害。 根据《腹壁外科杂誌》报道,女性腹股沟疝气的终生发生率为 3% 至 6%,男性为 27% 至 43%,老年人的盛行率更高。 这增加了老年人对疝气修復的需求。
本报告调查了全球软组织修復市场,提供市场定义和概述、市场规模趋势和预测、各个细分市场和地区的详细分析、行业结构以及影响市场成长的因素分析、案例研究、竞争格局、主要公司简介等等。
The global soft tissue repair market is projected to witness a CAGR of 4.48% during the forecast period 2024-2031, growing from USD 14.51 billion in 2023 to USD 20.61 billion in 2031. The major factors supporting the growth of the market include increased provision of grants that support research activities related to soft tissue repair, the growing geriatric population, rising incidences of sports-related injuries, and novel product launches.
The growth of the aging population is bolstering the demand for soft tissue repair solutions as they are more susceptible to the requirement of soft tissue repair solutions owing to their vulnerability to various afflictions. As an individual age, the bone mineral density decreases, increasing the occurrence of fractures and propelling the requirement for orthopedic repair solutions. Additionally, increasing incidences of sports related injuries are also supporting the growth of the market as they are boosting the requirement for different types of soft tissue repair solutions. Due to the increasing demand for technologies and products to repair soft tissues, several leading market players and start-ups are heavily investing in launching novel products and technologies.
Various studies are also being conducted by different companies and research institutions to support the development of novel products and assess the safety of existing solutions. For instance, Tissium, a France-based biotechnology company is conducting an interventional study to capture preliminary performance and safety of the Adhesive Hernia Repair System (TAHRS) for Atraumatic Laparoscopic repair of hernia. The study is expected to conclude in December 2024.
Rising Emphasis on Research and Development Activities Support Market Growth
Over the past few years, various leading market players and startups have steadily increased investments in various research and development activities to promote the development of technologically advanced soft tissue repair products. For instance, Regenosca, a Switzerland-based startup is involved with the development of implants that are engineered as a noninvasive alternative to the patient's tissue grafts. The solution developed by the company targets patients who require an autograft soft tissue repair surgery. With the help of TissueSpan implants, patients can avoid having a second surgical site, reducing the risk of complications, surgery time, and pain. The next product in the startup's pipeline is an implant for oesophagus reconstruction to replace the currently used patient's intestinal tissue or stomach.
Various regulatory bodies are also providing clearance for different products and expanding their indications of use. For instance, in 2023, the Food and Drug Administration (FDA) granted 510(k) clearance to three surgical mesh products. This clearance has expanded their indication for use. The intended use of surgical mesh products is the reinforcement of soft tissues where weaknesses exist.
Increasing Incidences of Sports Related Injuries and Aging Population Boost Market Demand
The expansion of the aging population and increasing incidences of sports related injuries are some of the major factors supporting the growth of the soft tissue repair market. Sports injuries commonly occur through direct impact or overuse of a certain body part. It can also occur if the application of force is greater than what the part of the body can structurally withstand. According to Johns Hopkins Medicine, approximately 30 million teenagers and children participate in some type of organized sport and over 3.5 million injuries occur every year. Various times the sports related injury requires that the soft tissues be repaired.
Meanwhile, the aging population is more susceptible to various soft tissue injuries as they go through metabolic inefficiencies and physiological changes. According to the Journal of Abdominal Wall Surgery, the lifetime occurrence of groin hernias is 3%-6% in women and 27%-43% in men, with high prevalence in elderly patients. Thus, propelling the requirement for hernia repair in the elderly.
North America Accounts for Significant Soft Tissue Repair Market Share
The market expansion in North America can be attributed to a wide range of drivers, including rising investments in the healthcare infrastructure, growing incidences of sports related injuries, increasing geriatric population, and strong presence of various leading market players and research institutions. The rise in the number of novel product launches is providing lucrative growth opportunities for the market. The growing investments in different research activities are further bolstering the market growth in the region. For instance, the Cleveland Clinic, Ohio, United States is involved in an interventional study to evaluate the effectiveness of ArthroFLEX(R) ECM scaffold graph for rotator cuff repair surgeries to reduce the rate of failure of rotator cuff repairs for massive and large rotator cuff repairs. The multi-center, randomized, and controlled clinical trial will involve seventy patients, with thirty-five patients being randomly assigned to each arm. The study is expected to be completed in June 2024.
Tissue Patch/Mesh Account for Significant Share of the Market
The segment growth can be attributed to the increasing utilization of synthetic mesh for different orthopedic procedures, including arthritis, owing to their ability to minimize surgery time. According to the data from the National Health Interview Survey (NHIS), during 2019-2021, an approximated 53.2 million adults in the United States were diagnosed with some form of arthritis, including gout, lupus, fibromyalgia, and rheumatoid arthritis. Novel product launches are also supporting the expansion of the segment. For instance, in 2021 Myriad Morcells(TM), a powdered format of Myriad Matrix(TM), received the 10(k) clearance by the FDA. The product was launched by the soft tissue regeneration company, Aroa Biosurgery Limited. The product easily optimizes contact with irregular wound beds.
Orthopedic Repair Segment Witnesses Significant Expansion
The growth of the orthopedic repair segment can be attributed to the increasing geriatric population and rising incidences of sports related injuries. As individuals age, bone mineral density decreases, resulting in increased brittleness of bones, making them more prone to orthopedic injuries. The risk of injury also increases if other health issues, including vision problems and unsteady balance, become more prominent. Due to such factors, the demand for orthopedic soft tissue repair procedures and the development of new products is increasing. Various biotechnology companies are also welcoming experts from the orthopedic industry to strengthen their orthopedic repair segment. For instance, ABANZA a leading Biotechnology company welcomed a new Executive Vice President for US Operations, with notable expertise in the orthopedic industry to ensure the commercialization of their WASHERCAP(TM) Soft Tissue Fixation System. WASHERCAP(TM) is the first in a series of innovative product releases that will focus on soft tissue fixation and repair.
Future Market Scenario (2024 - 2031F)
With the help of their recently secured funding, ZuriMED a Zurich-based biotechnology company, is expected to obtain regulatory approval for their initial product that will focus on repairing shoulder rotator cuff injuries. The company plans on entering the surgical device market in Europe and the United States over the course of three years.
Various research organizations and scientific institutions are being rewarded with funding and grants to support soft tissue restoration, promoting novel research, and supporting the growth of the market. For instance, in 2023, Penn State chemical engineering and reconstructive surgery researchers received a four-year, USD 3 million grant from the National Institutes of Health's National Heart, Lung, and Blood Institute to develop new methods of restoring soft tissue loss in patients with the help of two coordinating revascularization techniques. The team of researchers plans to combine a microsurgical tactic known as vascular micropuncture with a class of protein-based granular hydrogel biomaterials.
Key Players Landscape and Outlook
Key participants in the soft tissue repair market include Arthrex, Inc., Baxter International Inc., Medtronic, Boston Scientific Corporation, and Stryker Corporation. The market expansion is supported by increasing cases of trauma, rising sports related injuries, and growing investments by various organizations towards the development of advanced technological solutions.
In 2023, ZuriMED Technologies, one of the leading biotechnology companies based in Zurich, announced that they raised €15 million for their minimally invasive tech that is expected to transform soft tissue repair. The company plans on using the funds to accelerate the acceptance and advancement of its Surgical-Fiberlock technology, the innovative solution that was specially designed for repairing soft tissues through minimally invasive surgical procedures. The funding round was joined by a group of private investors that included prominent orthopedic surgeons from Germany, Switzerland, France, and the United States and Yellowstone Holding AG and led by Chindex Medical Limited.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work